Why is Lupin falling/rising?

Recent Price Movement and Market Context

Lupin’s stock has demonstrated resilience in recent trading sessions, gaining 2.92% over the past three days. This upward momentum is notable as the stock outperformed its sector by 1.47% on the day, signalling investor confidence relative to its peers. The current price is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which often serves as a technical endorsement for continued strength.

Comparing Lupin’s returns against the benchmark Sensex reveals a mixed but encouraging picture. While the stock has underperformed the Sensex year-to-date with a decline of 10.16% against the benchmark’s 9.12% gain, it has outpaced the index over the medium and long term. Over three years, Lupin has delivered a remarkable 181.06% return compared to Sensex’s 37.24%, and over five years, it has gained 124.80% versus the Sensex’s 84.97%. This long-term outperformance underlines the company’s sustained growth trajectory despite short-term volatility.

Fundamental Strength Supporting the Rally

Lupin’s recent quarterly results have been a key catalyst for the stock’s rise. The company reported a profit before tax excluding other income (PBT LESS OI) of ₹1,916.97 crores for the quarter ended September 2025, marking an impressive growth of 82.3% compared to the previous four-quarter average. This surge in profitability is complemented by a high return on capital employed (ROCE) of 22.22% for the half-year, indicating efficient utilisation of capital resources.

Operating profit to interest ratio also reached a peak of 21.76 times, reflecting strong operational earnings relative to interest expenses and signalling financial robustness. Lupin’s low average debt-to-equity ratio of 0.10 times further underscores its conservative capital structure, reducing financial risk and enhancing investor appeal.

Moreover, the company’s net sales have grown at an annual rate of 10.57%, while operating profit has expanded by 37.09%, highlighting healthy top-line and bottom-line growth. Despite a modest negative return of 0.24% over the past year, Lupin’s profits have surged by 64.7%, resulting in an attractive price-to-earnings growth (PEG) ratio of 0.4. This valuation metric suggests the stock is undervalued relative to its earnings growth potential, making it appealing for long-term investors.

Investor Participation and Liquidity Considerations

While the stock has been gaining, investor participation has shown some moderation. Delivery volume on 11 Dec was 3.45 lakh shares, down by 50.68% compared to the five-day average delivery volume. This decline in participation could indicate cautious trading or profit booking by some investors. Nevertheless, the stock remains sufficiently liquid, with a trade size capacity of approximately ₹4.05 crores based on 2% of the five-day average traded value, ensuring ease of entry and exit for market participants.

Institutional investors hold a significant 47.05% stake in Lupin, reflecting confidence from well-resourced and informed market players who typically conduct thorough fundamental analysis. Their involvement often provides stability and support to the stock price during market fluctuations.

Valuation and Long-Term Outlook

Lupin’s return on equity (ROE) stands at a robust 22%, and the stock trades at a price-to-book value of 4.9, which is considered attractive given its growth profile and profitability metrics. The stock is currently trading at a discount relative to its peers’ historical valuations, offering potential upside for investors seeking value in the pharmaceuticals sector.

Despite the year-to-date underperformance relative to the Sensex, Lupin’s strong fundamentals, improving profitability, and technical strength suggest a positive outlook. The company’s consistent growth in net sales and operating profit, combined with prudent financial management, positions it well for sustainable gains in the medium to long term.

Investors should, however, monitor trading volumes and broader market conditions, as reduced participation may affect short-term price movements. Overall, Lupin’s recent price rise is well supported by solid earnings growth, favourable valuation, and institutional backing.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →